Inactive

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order to Illumina for purchase of NovaSeq X plus sequencing instrument. Illumina is the sole ven... The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order to Illumina for purchase of NovaSeq X plus sequencing instrument. Illumina is the sole vendor of the NovaSeq X Plus Instrument. There are other vendors that supply instruments that can do Next Generation Sequencing; however, these other instruments do not have the ability to do both human genome and exome sequencing using SBS technology with the requirements listed above in the description. There are several vendors that offer next generation sequencing instruments including Thermo Fisher Scientific, Oxford Nanopore, MGI and PacBio. None of these four other manufacturers use SBS technology, rather the Thermo Scientific (Ion Torrent S5 and Genexus Systems) and the Oxford Nanopore (PromethION systems) use semiconductors for sequencing, the MGI (DNBSeQ-T7 system) uses a proprietary DNA nanoball technology and the PacBio (Revio, Onso and Sequel systems) uses sequencing by binding (SBB) for longer reads and is considered third-generation sequencing, not Next Generation Sequencing. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) (SAP) and 41 U.S.C. 3304(a)(1).. Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive quotations; however, all quotations/responses received within fifteen (15) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to Marva Lewis at knn5@cdc.gov by 4:00 pm EST on March 29, 2023